Stifel reiterates Buy rating on Xenon Pharmaceuticals stock, cites pain portfolio
PositiveFinancial Markets

Stifel has reaffirmed its Buy rating on Xenon Pharmaceuticals, highlighting the company's promising pain portfolio. This endorsement is significant as it reflects confidence in Xenon's potential to address unmet medical needs in pain management, which could lead to increased investor interest and support for the company's growth.
— Curated by the World Pulse Now AI Editorial System